News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
413,494 Results
Type
Article (37096)
Company Profile (67)
Press Release (376331)
Section
Business (115971)
Career Advice (1398)
Deals (24378)
Drug Delivery (89)
Drug Development (62495)
Employer Resources (105)
FDA (10430)
Job Trends (9323)
News (218170)
Policy (25913)
Tag
Academia (2004)
Alliances (42738)
Alzheimer's disease (1270)
Approvals (10391)
Artificial intelligence (115)
Bankruptcy (233)
Best Places to Work (7890)
Breast cancer (152)
Cancer (1146)
Cardiovascular disease (87)
Career advice (1172)
CAR-T (78)
Cell therapy (227)
Clinical research (49591)
Collaboration (477)
Compensation (249)
COVID-19 (2476)
Data (1113)
Diabetes (154)
Diagnostics (3591)
Drug pricing (86)
Earnings (40464)
Employer resources (97)
Events (48043)
Executive appointments (224)
FDA (11010)
Funding (349)
Gene therapy (180)
GLP-1 (628)
Government (4081)
Healthcare (12018)
Infectious disease (2569)
Interviews (246)
IPO (10581)
Job creations (1788)
Job search strategy (1005)
Layoffs (268)
Legal (7046)
Lung cancer (173)
Lymphoma (78)
Manufacturing (163)
Medical device (6443)
Medtech (6445)
Mergers & acquisitions (14009)
Metabolic disorders (440)
Neuroscience (1598)
NextGen: Class of 2025 (3854)
Non-profit (2970)
Northern California (1232)
Obesity (261)
Opinion (183)
Parkinson's disease (99)
Patents (98)
People (26003)
Phase I (15108)
Phase II (21635)
Phase III (17199)
Pipeline (481)
Policy (78)
Postmarket research (1931)
Preclinical (6416)
Radiopharmaceuticals (206)
Rare diseases (214)
Real estate (2667)
Regulatory (16181)
Research institute (1803)
Resumes & cover letters (209)
Southern California (1012)
Startups (1992)
United States (10113)
Vaccines (609)
Weight loss (210)
Date
Last 7 days (451)
Last 30 days (1236)
Last 365 days (23241)
2025 (1020)
2024 (23519)
2023 (26589)
2022 (34855)
2021 (37459)
2020 (35397)
2019 (29301)
2018 (22172)
2017 (21155)
2016 (19774)
2015 (22698)
2014 (16989)
2013 (14051)
2012 (14756)
2011 (15301)
2010 (13896)
Location
Africa (587)
Arizona (79)
Asia (26721)
Australia (4893)
California (2646)
Canada (1008)
China (261)
Colorado (112)
Connecticut (116)
Europe (64042)
Florida (383)
Georgia (93)
Illinois (236)
Indiana (152)
Maryland (513)
Massachusetts (1977)
Michigan (89)
Minnesota (111)
New Jersey (801)
New York (818)
North Carolina (406)
Northern California (1232)
Ohio (88)
Pennsylvania (611)
South America (823)
Southern California (1012)
Texas (350)
Washington State (256)
413,494 Results for "brain ag".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Press Releases
Firefly Neuroscience Discovers Breakthrough Cognitive Brain Age Biomarker Using its FDA-Cleared BNA™ Platform
January 14, 2025
·
5 min read
Brain cancer
Biopharma Takes on Deadly Brain Cancer After Decades of Failure
Emboldened by technological advances and a deeper knowledge of glioblastoma, Merck, Kazia Therapeutics, CorriXR Therapeutics and others are targeting the often-fatal brain tumor.
December 2, 2024
·
7 min read
·
Kate Goodwin
Approvals
PTC Wins First FDA Nod for Direct-to-Brain Gene Therapy, Targets Ultrarare Disease
The FDA has followed in the footsteps of its European counterparts and granted accelerated approval to PTC Therapeutics’ gene therapy Kebilidi for AADC deficiency. It is the first approved gene therapy to be delivered directly to the brain.
November 14, 2024
·
2 min read
·
Tristan Manalac
Alzheimer’s disease
Lilly Lowers Brain Swelling With Modified Dosing of Alzheimer’s Drug Kisunla
Approved by the FDA in July to treat adults with early symptomatic Alzheimer’s disease, Eli Lilly’s Kisunla reduced the brain swelling of patients in a late-stage trial following an adjusted dosing regimen.
October 30, 2024
·
2 min read
·
Tristan Manalac
Business
Io Therapeutics, Inc., presented data from studies of IRX4204, the company’s phase II clinical stage RXR agonist for treatment of normal aging-related neurodegeneration, at the FASEB Science Research Conference on Cellular and Molecular Mechanisms of Brain Aging
September 18, 2024
·
3 min read
Kizoo leads financing round in Reservoir Neuroscience to restore health to the aging brain
Reservoir Neuroscience announced today the completion of a $4M financing round to support the development of new therapies for age-related neurodegeneration.
January 18, 2024
·
3 min read
Pharm Country
Reactivate, repurpose, and rewire the brain
Developing brains become shaped by the sights, sounds, and experiences of early life. The brain’s circuits grow more stable as we age.
December 28, 2023
·
2 min read
Deals
Ad hoc: Novartis BidCo Germany AG Intends to Implement a Merger Squeeze-out of MorphoSys AG’s Minority Shareholders
MorphoSys AG announces that Novartis BidCo Germany AG informed the MorphoSys AG Management Board of its intention to merge MorphoSys AG as transferring company into Novartis BidCo Germany AG.
June 20, 2024
·
4 min read
Finding the sweet spot in brain development
Not everything in the brain is meant to last. As our brains assemble, trillions of neural connections have to be built or torn down at the right time and place.
July 1, 2024
·
2 min read
Vaccines
CDC Panel Recommends Merck and Pfizer Pneumococcal Vaccines for Adults Aged 50–64
The CDC’s Advisory Committee on Immunization Practices on Wednesday backed the use of Merck’s Capvaxive and Pfizer’s Prevnar 20 in adults between 50-64 years of age, opening a bigger market for the respective companies.
October 24, 2024
·
2 min read
·
Tristan Manalac
1 of 41,350
Next
